Physician profile
Robert D Kirk
NPI 1689672230
$1,257.56
in general payments reported to CMS, 2019-2025
22 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.47 · 2023: $460 · 2024: $360 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891 · Honoraria: $300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.09 |
| Honoraria | $300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.15 | 2023-2024 | |
| Chiesi USA, INC. | $300.00 | 2025 | Juxtapid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.18 | 2023-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $54.58 | 2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.28 | 2024 | Jardiance |
| Becton, Dickinson and Company | $47.00 | 2024-2025 | Site-Rite, Introducer Needle |
| Mallinckrodt Hospital Products INC. | $38.62 | 2024 | Terlivaz |
| Axsome Therapeutics, INC. | $35.07 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $34.04 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $31.86 | 2023-2024 | Invega, Xarelto |
| Alkermes, INC. | $29.16 | 2025 | Aristada, Lybalvi |
| Regeneron Healthcare Solutions, INC. | $28.78 | 2024 | Dupixent |
| Abbott Laboratories | $28.41 | 2023 | Cardiomems |
| Pfizer INC. | $23.81 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $22.34 | 2024 | Abilify Asimtufii |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $19.97 | 2024 | Smartvest |
| Coopersurgical, INC. | $19.47 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.97 | 2023 | Inpefa |
| Insmed, INC. | $17.44 | 2024 | Arikayce |
| Biomerieux INC | $16.88 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
| Amgen INC. | $15.55 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $15.00 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.